DEVELOPMENT AND EVALUATION OF FLOATING DRUG DELIVERY SYSTEM FOR DIABETES MELLITUS.

Diabetes Mellitus is most common endocrine disease. Diabetes Mellitus is defined conventionally as a lack of insulin secretion due to destruction of pancreatic β- cells. Diabetes is not a single disease entity, but rather a group of metabolic disorders sharing a commonunderlying feature of hyperglycemia. Hyperglycemia in diabetes, results from defects in insulin secretion, insulin action or both. Rosiglitazone Maleate is antidiabetic drug in Thiazolidinedioneclass of drugs has been used for treatment of Diabetes type II. Rosiglitazone is a highly selective and potent agonist for the Peroxisome Proliferator-Activated Receptor-gamma (PPARγ).Activation of PPARγ nuclear receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization.Rosiglitazone Maleate is readily soluble in ethanol and a buffered aqueous solution with pH of2.3; solubility decreases with increasing pH in the physiological range. Thus Rosiglitazone Maleate is needed to be formulated in GRDDS.In present investigation core tablet formulated with hydrophobic meltable binder such as Compritol 888 and Precirol ATO 5 with drug: polymer in 1:1, 1:2 ratio. Then, by using 32 full factorial design the formulations in suitable combinations formulated and tablets were evaluated.HPMC K100M and Sodium bicarbonate were selected as independent parameters in factorial design. Total floating time and floating lag time were selected as dependent parameters.The final formulations N7 and N8 were found to be optimized and follows Peppas model for drug release suggesting that drug release is anomalous from dosage form.